Drotaverine HydrochlorideThird Party Manufacturing in India

Drotaverine Hydrochloride works by directly relaxing smooth muscle tissue to relieve painful spasms and cramps throughout the body.

The molecule acts as a selective inhibitor of the phosphodiesterase-4 (PDE4) enzyme, which is responsible for breaking down cyclic adenosine monophosphate (cAMP) in smooth muscle cells. By blocking PDE4, drotaverine increases intracellular cAMP levels, which in turn inactivates myosin light chain kinase. This prevents the phosphorylation of myosin and blocks muscle contraction, resulting in smooth muscle relaxation. Additionally, it exhibits mild calcium channel blocking properties, reducing calcium entry into cells to further promote relaxation.

Unlike anticholinergic antispasmodic drugs, Drotaverine Hydrochloride does not block acetylcholine receptors. This key differentiator allows it to relieve smooth muscle spasms without causing dry mouth, blurred vision, or urinary retention. It is highly effective and well-tolerated for patients experiencing gastrointestinal, biliary, or genitourinary colicky pain.

Therapeutic Uses

Drotaverine Hydrochloride is prescribed for the treatment of:

• Gastrointestinal Spasms: Relieves abdominal pain associated with irritable bowel syndrome (IBS), enteritis, gastritis, and peptic ulcers.
• Biliary Colic: Indicated for spasms of the biliary tract due to cholelithiasis, cholecystitis, and cholangitis.
• Renal Colic: Used to manage acute, severe pain caused by kidney stones, ureterolithiasis, and cystitis.
• Obstetric and Gynecological Spasms: Prescribed for painful menstruation (dysmenorrhea) and to facilitate cervical dilation during labor.

Why Manufacturers Choose Drotaverine Hydrochloride

Drotaverine Hydrochloride is a highly popular antispasmodic molecule with steady year-round demand in Asian, Eastern European, and Latin American markets. Since it provides rapid pain relief without anticholinergic side effects, it is a preferred choice for clinicians managing acute colic. For third party manufacturers, producing Drotaverine Hydrochloride injections (40mg/2ml) offers a high-volume liquid injectable line with strong market penetration. Sourcing from a WHO-GMP certified facility in India ensures sterile ampoule filling, stable formulation chemistry, and professional packaging suited for global distribution networks.

This makes Drotaverine Hydrochloride one of the most sought-after antispasmodics for third party manufacturing in India, with consistent demand from PCD franchise operators and retail distributors.